Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.65 |
| ▸ | HTR3B | O95264 | 4/20 | 0.65 |
| ▸ | HTR3A | P46098 | 4/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | HTR1A | P08908 | 4/20 | 0.65 |
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922419 | 1.00 | HTR7 (0.65) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL3072479 | 0.98 | HTR7 (0.62) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL116919 | 0.93 | ADRB1 (0.57) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL6942579 | 0.85 | ADRA2C (0.80) | HTR7HTR1AHTR6CYP3A4HTR2A | |
| Phenylpiperazine SCHEMBL29235019 | 0.84 | ADRB1 (0.80) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL8709443 | 0.84 | DRD2 (0.85) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL7077636 | 0.83 | ADRA2C (0.77) | HTR7HTR1ATHRBHTR6TP53 | |
| Tert-Butyl Formate SCHEMBL27721029 | 0.82 | ADRB1 (0.51) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL17276711 | 0.82 | ADRB1 (0.67) | HTR7ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL15289763 | 0.81 | ADRA2C (0.68) | THRBTP53CYP3A4HTTADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163279-A3 | LOW-POWER WIRELESSLY-LINKED RFID TRACKING SYSTEM | ROSE MARK D (US) | 2012-05-10 | — | — | WO | claimed |
| EP-1592425-A4 | NEW ARYLPIPERAZINYL COMPOUNDS | EPIX DELAWARE INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1592425-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20040220192-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2004-11-04 | — | — | US | claimed |
| WO-2004069794-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-12078634-B2 | Broad spectrum kinase binding agents | PROMEGA CORPORATION (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20230194515-A1 | BROAD SPECTRUM KINASE BINDING AGENTS | PROMEGA CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-11442063-B2 | Broad spectrum kinase binding agents | PROMEGA CORPORATION (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| CN-1433407-A | Bis-aryl sulfones | PHARMACIA & UP JOHN CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | HTR7 3355/4885ADRB1 883/4885HTR3E 2939/4885 |
| US-11442063-B2 | Broad spectrum kinase binding agents | MAP4K2, MAP3K20, MAP4K1 | HTR7 3902/4885ADRB1 4020/4885HTR3E 3467/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | HTR7 3355/4885ADRB1 883/4885HTR3E 2939/4885 |
| US-20230194515-A1 | BROAD SPECTRUM KINASE BINDING AGENTS | MAP4K2, MAP3K20, MAP4K1 | HTR7 3902/4885ADRB1 4020/4885HTR3E 3467/4885 |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | HTR7 2537/4885ADRB1 1133/4885HTR3E 2764/4885 |
| US-20040220192-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | HTR7 7/4885ADRB1 28/4885HTR3E 15/4885 |
| US-12078634-B2 | Broad spectrum kinase binding agents | MAP4K2, MAP3K20, MAP4K1 | HTR7 3902/4885ADRB1 4020/4885HTR3E 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.